Citation | Devasthale, P; Wang, Y; Wang, W; Fevig, J; Feng, J; Wang, A; Harrity, T; Egan, D; Morgan, N; Cap, M; Fura, A; Klei, HE; Kish, K; Weigelt, C; Sun, L; Levesque, P; Moulin, F; Li, YX; Zahler, R; Kirby, MS; Hamann, LG Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778). J Med Chem56:7343-57 (2013) [PubMed] Article |
---|
SMILES | CCN(CC)C(=O)CCn1cc2[nH]c(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2c1=O |(29.61,-4.69,;30.38,-3.36,;31.92,-3.35,;32.69,-4.68,;34.23,-4.67,;32.68,-2.01,;31.9,-.68,;34.22,-2,;35,-3.33,;36.54,-3.33,;37.44,-2.07,;38.92,-2.54,;40.25,-1.77,;41.58,-2.54,;42.91,-1.76,;41.59,-4.09,;42.92,-4.85,;44.25,-4.08,;40.25,-4.86,;40.25,-6.4,;38.91,-7.16,;38.91,-8.7,;40.24,-9.47,;40.24,-11.01,;41.58,-8.7,;41.58,-7.16,;42.91,-6.39,;38.92,-4.09,;37.45,-4.57,;36.99,-6.04,)| |